多发性骨髓瘤的进展是由LILRB1通过GATA2-SAGE1通路调节的
Chiqi Chen1, Xuanyi Zhou1, Liyuan Cao1
1Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
白细胞Ig类受体亚家族B (LILRB1) 在多发性骨髓瘤 (MM) 中被上调,并驱动癌症生长. 向LILRB1可能为MM患者提供新的免疫疗法策略.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
背景情况:
- 多发性骨髓瘤 (MM) 是一种血细胞恶性瘤,尽管目前的免疫疗法,但存活率很低.
- 创新的免疫疗法对于改善MM患者的治疗结果至关重要.
- 白细胞Ig类受体亚家族B (LILRB1) 的作用,一个免疫检查点,在MM中仍然不清楚.
研究的目的:
- 研究LILRB1在多发性骨髓瘤中的作用和分子机制.
- 为了确定LILRB1表达和患者存活率之间的相关性.
- 探索LILRB1作为MM的潜在治疗点.
主要方法:
- 在MM患者和细胞系中评估LILRB1表达.
- 在MM细胞中进行LILRB1淘汰实验.
- 在小鼠模型中评估了LILRB1敲击对MM细胞亡,药物敏感性和瘤生长的影响.
- 研究了下游的信号通路,包括GATA2和SAGE1.
主要成果:
- 在MM患者和细胞系中,LILRB1显著上调,与存活率负相关.
- LILRB1 knockdown 诱导了MM细胞亡,增加了对博特佐米布的敏感性,并降低了瘤性.
- LILRB1激活GATA2,通过GATA2-SAGE1通路维持MM细胞的增殖.
结论:
- 在MM的进展和生存中,LILRB1起着至关重要的作用.
- 准LILRB1为多发性骨髓瘤提供了一个有前途的新型免疫治疗策略.
- GATA2-SAGE1通路是LILRB1促进MM的关键机制之一.
更多相关视频
10:21Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
相关概念视频
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
TGF - β Signaling Pathway
Abnormal Proliferation
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
Regulation of Expression at Multiple Steps
